GlobeNewswire: Nobilis Therapeutics, Inc. Contains the last 10 of 4 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:06:46ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/10/30/2117793/0/en/Nobilis-Therapeutics-to-Present-at-CapCon-2020-Venture-Conference.html?f=22&fvtc=4&fvtv=34861Nobilis Therapeutics to Present at CapCon 2020 Venture Conference2020-10-30T13:00:00Z<![CDATA[PORTLAND, Ore., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Nobilis Therapeutics, a late stage biotechnology company that is developing a drug-device combination for treatment of psychiatric disorders will present at the virtual CapCon 2020 Venture Conference, Nov 16-17.]]>https://www.globenewswire.com/news-release/2018/02/23/1386856/0/en/Nobilis-Therapeutics-Presents-Its-PTSD-Clinical-Development-Program-To-The-US-Congress.html?f=22&fvtc=4&fvtv=34861Nobilis Therapeutics Presents Its PTSD Clinical Development Program To The US Congress2018-02-23T20:19:25Z<![CDATA[WASHINGTON, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Dr. Edward Meloni, PhD of McLean Hospital (Harvard Medical School Affiliate) and Dr. Vlad Bogin, CEO and Founder of Nobilis Therapeutics earlier this week presented PTSD clinical development program to the House of Representatives Committee on Veterans’ Affairs.]]>https://www.globenewswire.com/news-release/2017/06/14/1019145/0/en/Nobilis-Therapeutics-NBTX-001-shows-promise-in-treatment-of-patients-with-Panic-Disorder.html?f=22&fvtc=4&fvtv=34861Nobilis Therapeutics’ NBTX-001 shows promise in treatment of patients with Panic Disorder2017-06-14T17:34:45Z<![CDATA[Study results published in Journal of Translational Medicine Study results published in Journal of Translational Medicine]]>https://www.globenewswire.com/news-release/2017/06/12/1017989/0/en/Nobilis-Therapeutics-Receives-a-Notice-of-Allowance-for-a-Patent-Covering-Treatment-of-Psychiatric-Disorders-With-Noble-Gases.html?f=22&fvtc=4&fvtv=34861Nobilis Therapeutics Receives a Notice of Allowance for a Patent Covering Treatment of Psychiatric Disorders With Noble Gases2017-06-12T22:57:36Z<![CDATA[PORTLAND, Ore., June 12, 2017 (GLOBE NEWSWIRE) -- Nobilis Therapeutics announced today that the patent that it had exclusively licensed from Partners HealthCare/McLean Hospital (an affiliate of Harvard University) has received a notice of allowance. The patent is titled "XENON AND/OR ARGON TREATMENT AS AN ADJUNCT TO PSYCHOTHERAPY FOR PSYCHIATRIC DISORDERS" and covers a wide range of noble gas uses in the treatment of psychiatric disorders.]]>